Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Masood Ahmad

Allergy & Immunology Seaman, OH Medical Doctor

NPI 1699856559 CMS profile 76431

230 Medical Center Dr, Seaman, OH 45679

Open in the dashboard

General payments

$5,250

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Masood Ahmad of Seaman, OH is reported in the CMS Open Payments database as having received $5,250 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74 1
2023 General $13 1
2022 General $1,307 62
2021 General $903 53
2020 General $1,252 65
2019 General $1,702 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Masood Ahmad
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Masood Ahmad were reported at $74. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Masood Ahmad Allergy & Immunology median Middle half National median
2019 $1,702 $378 $115–$1,178 $163
2020 $1,252 $303 $75–$1,581 $114
2021 $903 $407 $122–$1,475 $132
2022 $1,307 $357 $120–$1,340 $149
2023 $13 $445 $124–$1,536 $160
2024 $0 $541 $129–$1,763 $164
2025 $74 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,714 85 payments
  2. Regeneron Healthcare Solutions, Inc. $868 44 payments
  3. Genzyme Corporation $548 32 payments
  4. Amgen Inc. $443 11 payments
  5. GlaxoSmithKline, LLC. $428 22 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $148 9 payments
  7. kaleo, Inc. $136 8 payments
  8. Covis Pharma B.V. $121 7 payments
  9. Novartis Pharmaceuticals Corporation $111 6 payments
  10. Tosoh Bioscience, Inc. $95 1 payment
  11. Other $637 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,155 256 payments
  2. Gift $95 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $868 44 payments
  2. DUPIXENT Immunology $680 42 payments
  3. SYMBICORT $573 30 payments
  4. FASENRA Respiratory $492 21 payments
  5. FASENRA Respiratory $466 17 payments
  6. BREZTRI $352 8 payments
  7. TEZSPIRE $260 2 payments
  8. DUPIXENT Immunology $238 12 payments
  9. NUCALA $236 10 payments
  10. AIMOVIG $200 2 payments
  11. Other $2,410 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record